Vico Therapeutics

Investor interest in biopharmaceutical opportunities is slowly but surely improving in 2024, including both private investors and public-sector funders of drug development infrastructure. In mid-month

Venture capital fundraising by biopharmaceutical companies plunged in the fourth quarter to $4.3bn, down from $6.2bn in the third quarter and below the $5.7bn raised in Q4 of 2022, according to the la

Venture capital investment in biopharmaceutical companies has been remarkable throughout 2020, both in terms of individual company fundraisings and new VC funds, including two funds totaling $755m tha

Venture capital investment in biopharmaceutical companies is booming in 2020. And while novel cancer and immuno-oncology programs continue to attract large sums, drug developers working on treatments